Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Faulty Hip Implants:...

    Faulty Hip Implants: JnJ willing to pay only Rs 25 lakh to victims

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-04-09T10:15:24+05:30  |  Updated On 9 April 2019 10:15 AM IST
    Faulty Hip Implants: JnJ willing to pay only Rs 25 lakh to victims

    JnJ has challenged the March 8 and March 28 orders of the Centre by which it has arrived at a compensation formula and asked the firm to abide by it. It has sought a stay on the Centre's two orders.


    New Delhi: The Delhi High Court Monday sought a response of the Centre on a plea by Johnson and Johnson challenging the orders by which it was directed to pay compensation to patients who received faulty hip implants made by the company.


    Justice Vibhu Bakhru issued a notice to the Centre on the petition and orally asked authorities not to take any steps against the firm till the next date of hearing.


    The company also informed the court that it was willing to pay Rs 25 lakh as compensation to the patients who were affected by its hip implants.


    The court asked the Centre, represented through central government standing counsel B S Shukla and Amit Mahajan, to seek instructions on the plea and the company's offer of Rs 25 lakh compensation and listed the matter for further hearing on May 2.


    The company has challenged the March 8 and March 28 orders of the Centre by which it has arrived at a compensation formula and asked the firm to abide by it. It has sought a stay on the Centre's two orders.


    "Many patients have exercised their remedies before the consumer courts. The actions of the respondents in unilaterally arriving at a compensation formula and further directing the petitioner to abide by the same in the absence of any legal basis thereto is arbitrary and devoid of any statutory power," the petition said.


    It said the recent orders of the Centre fixing the compensation is based on a formula and a set of expert committees reports and recommendations which have already been challenged by the company and are pending in the high court.


    It added that the Drugs and Cosmetics Act does not have any provisions that provide for a formula for payment of compensation in the matters pertaining to medical devices.


    Also Read: JnJ Faulty Hip Implants: 7 more patients found fit for compensation


    In the earlier petition filed in December last year, the company has sought quashing of a government's press release informing the general public about the formula worked out by an expert committee to compensate patients who received the faulty hip implants produced by the pharma major's subsidiary, DePuy Orthopaedics Inc (USA).


    It has also challenged the report of the expert committee -- headed by R K Arya, Director, Sports Injury Centre -- which worked out the compensation formula.


    Besides, it has also sought quashing of the report of another committee -- headed by Arun Agarwal, Professor of ENT, Maulana Azad Medical College -- which was appointed by the Health Ministry for looking into the allegations of faulty hip replacement implants.


    According to the Arya committee report, compensation payable to patients would be determined in terms of the disability by the faulty hip implants in relation to their age.


    Those between 20 to 35 years would get compensation between Rs 58.08 lakh and Rs 49.66 lakh for 20 to 30 per cent disability; Rs 77.63 lakh to Rs 69.41 lakh for 30 to 40 per cent disability; Rs 100.17 lakh to 89.32 lakh for 40 to 50 per cent disability and Rs 122.71 lakh to Rs 109.15 lakh over 60 per cent disability, the press release had stated.


    It has said those between 35 to 60 years will get compensation between Rs 49.66 lakh and Rs 33.63 lakh for 30 per cent disability; Rs 69.49 lakh to Rs 44.45 lakh for 30 to 40 per cent disability, Rs 89.32 lakh to Rs 57.26 lakh for 40 to 50 per cent disability and Rs 109.15 lakh to 69.08 lakh for over 60 per cent disability.


    Those above 65 years will get compensation of 30 lakh for 20 to 30 per cent disability, Rs 40 lakh for 30 to 40 per cent ability, Rs 50 lakh for 40 to 50 per cent and 60 lakh for over 60 per cent disability, it had said.


    The pharma major had earlier told the court that as a result of the press release, people are "landing at its doorstep" for compensation and contended that the government's public announcement was made without any legal basis.


    Public interest litigation (PIL), which was earlier before the Supreme Court, has alleged that "faulty" and "deadly" hip implants have been fitted into the bodies of 4,525 Indian patients.


    The plea has contended that DePuy makes, sells and exports medical implants, including articular surface replacements (ASR) hip implants which have been withdrawn by the firms on their own in 2010 on the ground that they were defective.


    According to the PIL, the firms "illegally sold DePuy ASR Hip Implants in India from 2005 to 2006".


    Also Read: MORE TEARS: After Talcum Powder, JnJ Baby Shampoo reveals presence of Carcinogens

    articular surface replacementASRcompensationcriminal negligenceDePuy Hip RecallDePuy ProstheticsDr r k aryaDrugs and Cosmetics Acthealth insurancehealth newsHealthcareHip Implant Patients Support Grouphip implantsHIPSJnJJohnsonJohnson and JohnsonMaulana Azad Medical CollegeNew Delhipharmapharma newspharma news indiaUnion Health Ministry
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok